Health Security Digest

  • The times of india

    ‘Avoid election rallies to prevent swine flu’

    18 March 2019 - Times of India

    With the deadly swine flu virus (H1N1) becoming highly active since the beginning of the year and 35 new cases being detected in the last few days, health experts warned people to cautious during the election season. The experts said that the virus could spread quickly at political meetings and rallies due to large gathering. 

  • DOH: Store water but avoid dengue

    17 March 2019 - The Inquirer.Net

    Health Secretary Francisco Duque III appealed to Metro Manila and Rizal residents suffering from the water supply crisis to be cautious about how they store water to prevent a possible outbreak of dengue, which was already breaking records in terms of number of cases and deaths. Duque on Friday said even a small amount of water, like that which fills a bottle cap, could serve as breeding ground for the dengue-carrying mosquito Aedes aegypti if left unattended.

  • Vietnam Net

    Lighting up hope from medical research

    16 March 2019 - Vietnam Net

    Vietnam so far has had to rely on foreign manufacturers for the supply of influenza vaccines. The best way to ensure access to these human lifesaving tools is to produce vaccines constantly and always be ready for pandemic response. Witnessing the achievements after much hardship, Dr. Le Van Be, former Head of the Institute of Vaccines and Medical Biologicals (IVAC), confidently affirmed that this is a resounding success in research cooperation between IVAC and international organisations, such as the World Health Organisation (WHO), the global health organisation PATH and the Biomedical Advanced Research and Development Authority (BARDA). The success has been also praised by the world, recognising the prestige and intelligence of the Vietnamese medical sector. It not only brings great benefits to public healthcare but will also supply vaccines to the world in the near future.

  • Workforce Development Action Package meeting Bangkok

    15 March 2019 - FETP - Thailand

    The GHSA Meeting on the Progress & Ways forward for the Regional StrategicFrameworks in Animal & Human Health on Workforce Development 13th-15th March 2019 , Arnoma Grand Hotel, Bangkok, Thailand.

  • Zika Virus Endemic In Thailand, Study Shows

    14 March 2019 - Asian Scientist

    Unlike in South America where the Zika virus disappears two or three years after outbreaks, Zika transmission in Thailand has persisted for at least 16 years. The Aedes mosquito is found in most tropical and subtropical countries, including Southeast Asia, and is a vector for the transmission of flaviruses such as the Zika virus. While the spread of Zika virus is well documented in South America, information on Zika outbreaks in Southeast Asia is scarce.

  • The elephant–livestock interface modulates anthrax suitability in India

    13 March 2019 - The Royal Society

    Michael G. Walsh et at.,

    Both biotic and abiotic features contributed to risk across multiple scales of influence. The elephant–livestock interface was the dominant feature in delineating anthrax suitability. In addition, water–soil balance, soil chemistry and historical forest loss were also influential. These findings suggest that the elephant–livestock interface plays an important role in the cycling of anthrax in India.

  • The Wired

    When It Comes to Disease, Why Wait for a Pandemic to Respond?

    13 March 2019 - Wired

    Via JHCHS

    Rapid response to a real-life pandemic is essential, and the role of community awareness and preparedness is critical—why wait for a real-life pandemic to learn how to respond? In the lead up to the O2 simulation, students participate in a two-week civics and science module on outbreak response, then take on roles as clinicians, epidemiologists, government officials, military, media, and the general population. During the simulation, students face the possibility of infection while carrying out these roles.

  • Centres for disease control and prevention

    Infections among Contacts of Patients with Nipah Virus, India

    12 March 2019 - Centers for Disease Control and Prevention

    Via CIDRAP

    Nipah virus (NiV) infection is an emerging zoonotic disease that has the potential to cause severe disease in both animals and humans. Fruit bats of the Pteropus genus (family Pteropodidae) are the natural hosts of NiV. Outbreaks of NiV have been reported from Malaysia, Singapore, Bangladesh, and eastern India; mortality rates are 40%–70%. We conducted a serosurvey of 155 healthcare workers and 124 household and community members who had close contact with 18 patients who had laboratory-confirmed Nipah virus infections in Kerala, India. We detected 3 subclinical infections; 2 persons had IgM and IgG and 1 only IgM against Nipah virus.


    Protection from Zika virus may lie in a protein derived from mosquitoes

    11 March 2019 -

    By targeting a protein found in the saliva of mosquitoes that transmit Zika virus, Yale investigators reduced Zika infection in mice. The finding demonstrates how researchers might develop a vaccine against Zika and similar mosquito-borne viruses, the study authors said.
    One source of a potential vaccine strategy is the Aedes aegypti mosquito that carries and transmits the virus. A Yale research team recently focused on proteins found in the saliva of these mosquitoes and how they might affect Zika transmission.

  • Money Control

    Bharat Biotech's Zika, Chikungunya vaccines to enter Phase II trials; focus now on private label market

    11 March 2019 - Money Control

    Viswanath Pilla

    So far there are no vaccines in the world against Zika and Chikungunya.  Both are viral diseases and spread primarily by mosquito bites. It takes around 10 to 15 years to complete all three phases of clinical trials of a vaccine before it can get marketing licensing. Phase-II trial takes around two years and the vaccine has to be tested on 200-300 patients. Vaccine maker Bharat Biotech International said two of its vaccines against Zika and Chikungunya will be entering phase-II clinical trials, where they will be tested on humans for safety and efficacy.


Subscribe to  Health Security Digest